Helpful Products for GLP-1 Treatment

Managing your GLP-1 medication is easier with the right tools:

• Sharps container — Essential for safe needle disposal. A sharps container is required for home use.
• Ginger products — Manage nausea with ginger chews or ginger tea.
• Water bottle — Stay hydrated to reduce side effects. A large water bottle helps you track intake.
• Electrolyte packets — Prevent dehydration. Liquid I.V. packets dissolve easily in water.

GLPSpot may earn from qualifying purchases.

Quick Comparison

	Zepbound	Retatrutide
Active drug	Tirzepatide	Retatrutide
Drug class	Dual GIP/GLP-1 agonist	Triple GIP/GLP-1/Glucagon agonist
FDA approval	Weight management (approved)	Phase 3 trials (positive results as of May 2026)
Dosing	Once weekly	Once weekly (in trials)
Status	Available now	Phase 3 complete (not yet FDA-approved)

What Makes Retatrutide Different?

Retatrutide mimics three hormones:

1. GLP-1 — signals fullness, slows digestion
2. GIP — works with GLP-1 to boost the effect
3. Glucagon — increases energy expenditure (burns more calories)

Zepbound uses the first two. Retatrutide adds the third.

Weight Loss Results

From clinical trials (as of May 2026):

• Zepbound: ~21% body weight loss at max dose
• Retatrutide (Phase 3): up to 28.7% body weight loss at 12 mg dose (TRIUMPH-4, 68 weeks)
• Retatrutide (Phase 3): up to 16.8% body weight loss in type 2 diabetes (TRANSCEND-T2D-1, 40 weeks)

Retatrutide has shown stronger results in Phase 3 trials. The added glucagon component appears to boost calorie burning on top of the fullness signals. The 28.7% weight loss seen in TRIUMPH-4 is the highest reported in any Phase 3 obesity trial so far.

Side Effects

Based on Phase 3 trial data, Retatrutide causes similar side effects:

• Nausea
• Decreased appetite
• Increased heart rate (from glucagon)
• Diarrhea or constipation
• Dysesthesia (tingling or burning sensation) — more common at higher doses

The glucagon component may cause a slightly higher heart rate, which is being monitored in trials.

Availability

Retatrutide is not yet FDA-approved. Two Phase 3 trials have reported positive results (TRIUMPH-4 and TRANSCEND-T2D-1). Seven more Phase 3 readouts are expected in 2026. The earliest likely FDA filing is late 2026 or 2027, with potential approval in 2027.

Cost

No pricing yet. Likely similar to Zepbound (~$1,060/month).

FAQ

When will retatrutide be available?

Retatrutide is not yet FDA-approved. Two Phase 3 trials have reported positive results as of May 2026, with seven more Phase 3 readouts expected in 2026. The earliest likely FDA filing is late 2026 or 2027, with potential approval in 2027.

How much more weight loss does retatrutide offer compared to Zepbound?

Phase 3 trials show retatrutide produced up to 28.7% body weight loss vs approximately 21% for Zepbound at maximum dose. That is roughly an 8 percentage point difference, though individual results vary and retatrutide is not yet approved.

Does retatrutide have more side effects than Zepbound?

Both drugs cause similar GLP-1 side effects like nausea and decreased appetite. Retatrutide may cause increased heart rate due to its glucagon component, which is not present in Zepbound. This is being closely monitored in trials.

Can I take Zepbound now and switch to retatrutide later?

Possibly, but talk to your doctor. Switching between GLP-1 medications is done clinically, but retatrutide will not be available until at least 2027. If Zepbound is working for you now, there is no urgent reason to plan a switch.

Bottom Line

Retatrutide offers stronger weight loss than Zepbound in Phase 3 trials — up to 28.7% vs around 21%. It is not available yet, but with positive Phase 3 results now in hand, the earliest possible approval is 2027. If Zepbound is working for you, stick with it. If you're not getting the results you want, talk to your doctor about current options.

Work with your healthcare provider to determine which medication is right for you. Individual results and experiences vary.